Bernard-Soulier Syndrome Treatment & Management
- Author: John D Geil, MD; Chief Editor: Robert J Arceci, MD, PhD more...
Medical Care
- Care of Bernard-Soulier syndrome (BSS) is generally supportive.
- Avoid antiplatelet medication, such as aspirin.
- Specific treatment of bleeding episodes includes the following:
- Antifibrinolytic agents, such as epsilon aminocaproic acid (Amicar) or tranexamic acid (Cyklokapron), may be useful for mucosal bleeding.
- For surgery or life-threatening hemorrhage, platelet transfusion is the only available therapy. Platelet transfusions should be reserved for surgery or potentially life-threatening bleeding. The patient may develop antiplatelet antibodies because of glycoproteins Ib/IX/V, which are present on the transfused platelets but absent from the patient's own platelets.
- Desmopressin acetate (DDAVP) has been shown to shorten the bleeding time in some, but not all, patients with Bernard-Soulier syndrome. DDAVP may be useful for minor bleeding episodes. The exact mechanism for this is unknown, but it may relate to increased levels of von Willebrand factor (vWF) binding to some residual glycoprotein Ib in patients without an absolute deficiency.
- Recombinant activated factor VII has been used in patients with congenital platelet disorders, including Bernard-Soulier syndrome.[5] Once again, the exact mechanism of action is unknown, but it may work by increasing thrombin generation and the deposition of fibrin at the site of vascular injury.
Consultations
- Consult a pediatric hematologist.
Activity
- For patients with moderate-to-severe symptoms, some restriction of activity may be necessary.
Young G, Luban N, White JG. Giant platelet disorders in African-American children misdiagnosed as idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. May-Jun 1999;21(3):231-6. [Medline].
Mahfouz RA, Bolz HJ, Otrock ZK, Bergmann C, Muwakkit S. Novel mutation in the glycoprotein Ibß in a patient with Bernard-Soulier syndrome: possibility of distant parental consanguinity. Blood Coagul Fibrinolysis. Feb 15 2012;[Medline].
Bartsch I, Sandrock K, Lanza F, Nurden P, Hainmann I, Pavlova A, et al. Deletion of human GP1BB and SEPT5 is associated with Bernard-Soulier syndrome, platelet secretion defect, polymicrogyria, and developmental delay. Thromb Haemost. Sep 2011;106(3):475-83. [Medline].
Savoia A, Pastore A, De Rocco D, Civaschi E, Di Stazio M, Bottega R, et al. Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations. Haematologica. Mar 2011;96(3):417-23. [Medline]. [Full Text].
Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch Pathol Lab Med. Dec 2007;131(12):1834-6. [Medline].
Cohn RJ, Sherman GG, Glencross DK. Flow cytometric analysis of platelet surface glycoproteins in the diagnosis of Bernard-Soulier syndrome. Pediatr Hematol Oncol. Jan-Feb 1997;14(1):43-50. [Medline].
Enomoto TM, Thorborg P. Emerging off-label uses for recombinant activated factor VII: grading the evidence. Crit Care Clin. Jul 2005;21(3):611-32. [Medline].
Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost. Jun 2005;93(6):1027-35. [Medline].
Hacihanefioglu A, Tarkun P, Gonullu E. Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard-Soulier syndrome. Thromb Res. 2007;120(3):455-7. [Medline].
Jantunen E. Inherited giant platelet disorders. Eur J Haematol. Oct 1994;53(4):191-6. [Medline].
Kunishima S, Kamiya T, Saito H. Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol. Nov 2002;76(4):319-27. [Medline].
Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood. Jun 15 1998;91(12):4397-418. [Medline]. [Full Text].
Mhawech P, Saleem A. Inherited giant platelet disorders. Classification and literature review. Am J Clin Pathol. Feb 2000;113(2):176-90. [Medline].
Nurden AT. Inherited abnormalities of platelets. Thromb Haemost. Aug 1999;82(2):468-80. [Medline].
Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost. Aug 2005;3(8):1773-82. [Medline].
Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis. Apr 2000;11 Suppl 1:S55-68. [Medline].
Tefre KL, Ingerslev J, Sorensen B. Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome. Haemophilia. Jan 2009;15(1):281-4. [Medline].
Watanabe R, Ishibashi T, Saitoh Y, et al. Bernard-soulier syndrome with a homozygous 13 base pair deletion in the signal peptide-coding region of the platelet glycoprotein Ib(beta) gene. Blood Coagul Fibrinolysis. Jun 2003;14(4):387-94. [Medline].
Zieger B, Jenny A, Tsakiris DA, et al. A large Swiss family with Bernard-Soulier syndrome - Correlation phenotype and genotype. Hamostaseologie. May 2009;29(2):161-7. [Medline].

